The company states: "Silo Pharma (SILO) announced promising results from a preclinical study on SPC-15. This new formulation, which targets both the serotonin 5-HT4 receptor, 5-HT4R, and the NMDA ...

SPC-14 has shown promising efficacy in preclinical studies, targeting both glutamate receptor NDMAR and serotonin 5-HT4 receptors, suggesting it may effectively address cognitive and ...

About SPC-15 SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA ...

About SPC-15 SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA ...

SARASOTA, FL, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations ...

About SPC-15 SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety.

Researchers have found that SSRI (Selective Serotonin Reuptake Inhibitors) antidepressants have the potential to improve certain cognitive functions, such as verbal memory. This work is presented ...